BioCentury
ARTICLE | Company News

Akers Biosciences, Jai Capital deal

May 26, 2014 7:00 AM UTC

Akers granted Jai non-exclusive rights to commercialize four of Akers' rapid tests in India. The products are Akers' PIFA Heparin/ PF4 test to detect heparin-induced thrombocytopenia (HIT) antibodies; PIFA Dengue Fever screening test for dengue fever; Battlefield Blood Transfusion Card to assess donor-patient blood grouping compatibility; and Tri-Cholesterol "Check" test for estimating total, HDL and LDL cholesterol levels. Akers said Jai plans to market the tests to the Indian military and potential Indian diagnostic partners. Akers also plans to grant an Indian diagnostic company non-exclusive rights to commercialize the tests to the hospital and surgery markets in India. Akers declined to disclose financial terms, and Jai Capital could not be reached. ...